Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 316

1.

Complement Activation and Thrombotic Microangiopathies.

Palomo M, Blasco M, Molina P, Lozano M, Praga M, Torramade-Moix S, Martinez-Sanchez J, Cid J, Escolar G, Carreras E, Paules C, Crispi F, Quintana LF, Poch E, Rodas L, Goma E, Morelle J, Espinosa M, Morales E, Avila A, Cabello V, Ariceta G, Chocron S, Manrique J, Barros X, Martin N, Huerta A, Fraga-Rodriguez GM, Cao M, Martin M, Romera AM, Moreso F, Manonelles A, Gratacos E, Pereira A, Campistol JM, Diaz-Ricart M.

Clin J Am Soc Nephrol. 2019 Nov 6. pii: CJN.05830519. doi: 10.2215/CJN.05830519. [Epub ahead of print]

PMID:
31694864
2.

Treatment for refractory lupus nephritis: Rituximab vs triple target therapy.

Cervera R, Mosca M, Ríos-Garcés R, Espinosa G, Trujillo H, Bada T, Praga M.

Autoimmun Rev. 2019 Oct 22:102406. doi: 10.1016/j.autrev.2019.102406. [Epub ahead of print] Review. No abstract available.

PMID:
31654743
3.

The authors reply.

Cavero T, Rodríguez de Córdoba S, Praga M.

Kidney Int. 2019 Nov;96(5):1239-1240. doi: 10.1016/j.kint.2019.08.014. No abstract available.

PMID:
31648698
4.

Renal damage secondary to check-point inhibitors.

Moliz C, Cavero T, Morales E, Gutiérrez E, Alonso M, Praga M.

Nefrologia. 2019 Oct 12. pii: S0211-6995(19)30145-6. doi: 10.1016/j.nefro.2019.05.004. [Epub ahead of print] English, Spanish. No abstract available.

5.

Complement inhibitors are useful in secondary hemolytic uremic syndromes.

Caravaca-Fontan F, Praga M.

Kidney Int. 2019 Oct;96(4):826-829. doi: 10.1016/j.kint.2019.07.006. No abstract available.

PMID:
31543153
6.

Acute kidney injury in interstitial nephritis.

Caravaca-Fontán F, Fernández-Juárez G, Praga M.

Curr Opin Crit Care. 2019 Dec;25(6):558-564. doi: 10.1097/MCC.0000000000000654.

PMID:
31503026
7.

Severe and malignant hypertension are common in primary atypical hemolytic uremic syndrome.

Cavero T, Arjona E, Soto K, Caravaca-Fontán F, Rabasco C, Bravo L, de la Cerda F, Martín N, Blasco M, Ávila A, Huerta A, Cabello V, Jarque A, Alcázar C, Fulladosa X, Carbayo J, Anaya S, Cobelo C, Ramos N, Iglesias E, Baltar J, Martínez-Gallardo R, Pérez L, Morales E, González R, Macía M, Draibe J, Pallardó L, Quintana LF, Espinosa M, Barros X, Pereira F, Cao M, Moreno JA, Rodríguez de Córdoba S, Praga M; Spanish Group for the Study of Glomerular Diseases (GLOSEN).

Kidney Int. 2019 Oct;96(4):995-1004. doi: 10.1016/j.kint.2019.05.014. Epub 2019 May 31.

PMID:
31420192
8.

NSAIDs and Nephrotic Syndrome.

Mérida E, Praga M.

Clin J Am Soc Nephrol. 2019 Sep 6;14(9):1280-1282. doi: 10.2215/CJN.08090719. Epub 2019 Aug 15. No abstract available.

PMID:
31416889
9.

Nrf2 Plays a Protective Role Against Intravascular Hemolysis-Mediated Acute Kidney Injury.

Rubio-Navarro A, Vázquez-Carballo C, Guerrero-Hue M, García-Caballero C, Herencia C, Gutiérrez E, Yuste C, Sevillano Á, Praga M, Egea J, Cannata P, Cortegano I, de Andrés B, Gaspar ML, Cadenas S, Michalska P, León R, Ortiz A, Egido J, Moreno JA.

Front Pharmacol. 2019 Jul 3;10:740. doi: 10.3389/fphar.2019.00740. eCollection 2019.

10.

IgA Nephropathy in Elderly Patients.

Sevillano AM, Diaz M, Caravaca-Fontán F, Barrios C, Bernis C, Cabrera J, Calviño J, Castillo L, Cobelo C, Delgado-Mallén P, Espinosa M, Fernandez-Juarez G, Fernandez-Reyes MJ, Garcia-Osuna R, Garcia P, Goicoechea M, Gonzalez-Cabrera F, Guzmán DA, Heras M, Martín-Reyes G, Martinez A, Olea T, Peña JK, Quintana LF, Rabasco C, López Revuelta K, Rodas L, Rodriguez-Mendiola N, Rodriguez E, San Miguel L, Sanchez de la Nieta MD, Shabaka A, Sierra M, Valera A, Velo M, Verde E, Ballarin J, Noboa O, Moreno JA, Gutiérrez E, Praga M; Spanish Group for the Study of Glomerular Diseases (GLOSEN).

Clin J Am Soc Nephrol. 2019 Aug 7;14(8):1183-1192. doi: 10.2215/CJN.13251118. Epub 2019 Jul 16.

PMID:
31311818
11.

Secondary atypical hemolytic uremic syndromes in the era of complement blockade.

Praga M, Rodríguez de Córdoba S.

Kidney Int. 2019 Jun;95(6):1298-1300. doi: 10.1016/j.kint.2019.01.043.

PMID:
31122707
12.

Glomerular Hematuria: Cause or Consequence of Renal Inflammation?

Moreno JA, Sevillano Á, Gutiérrez E, Guerrero-Hue M, Vázquez-Carballo C, Yuste C, Herencia C, García-Caballero C, Praga M, Egido J.

Int J Mol Sci. 2019 May 5;20(9). pii: E2205. doi: 10.3390/ijms20092205. Review.

13.

Curcumin reduces renal damage associated with rhabdomyolysis by decreasing ferroptosis-mediated cell death.

Guerrero-Hue M, García-Caballero C, Palomino-Antolín A, Rubio-Navarro A, Vázquez-Carballo C, Herencia C, Martín-Sanchez D, Farré-Alins V, Egea J, Cannata P, Praga M, Ortiz A, Egido J, Sanz AB, Moreno JA.

FASEB J. 2019 Aug;33(8):8961-8975. doi: 10.1096/fj.201900077R. Epub 2019 Apr 29.

PMID:
31034781
14.

Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials.

Heerspink HJL, Greene T, Tighiouart H, Gansevoort RT, Coresh J, Simon AL, Chan TM, Hou FF, Lewis JB, Locatelli F, Praga M, Schena FP, Levey AS, Inker LA; Chronic Kidney Disease Epidemiology Collaboration.

Lancet Diabetes Endocrinol. 2019 Feb;7(2):128-139. doi: 10.1016/S2213-8587(18)30314-0. Epub 2019 Jan 8.

PMID:
30635226
15.

Fibroblast growth factor-23 promotes rhythm alterations and contractile dysfunction in adult ventricular cardiomyocytes.

Navarro-García JA, Delgado C, Fernández-Velasco M, Val-Blasco A, Rodríguez-Sánchez E, Aceves-Ripoll J, Gómez-Hurtado N, Bada-Bosch T, Mérida-Herrero E, Hernández E, Praga M, Salguero R, Solís J, Arribas F, Delgado JF, Bueno H, Kuro-O M, Ruilope LM, Ruiz-Hurtado G.

Nephrol Dial Transplant. 2019 Nov 1;34(11):1864-1875. doi: 10.1093/ndt/gfy392.

PMID:
30629224
16.

Is there long-term value of pathology scoring in immunoglobulin A nephropathy? A validation study of the Oxford Classification for IgA Nephropathy (VALIGA) update.

Coppo R, D'Arrigo G, Tripepi G, Russo ML, Roberts ISD, Bellur S, Cattran D, Cook TH, Feehally J, Tesar V, Maixnerova D, Peruzzi L, Amore A, Lundberg S, Di Palma AM, Gesualdo L, Emma F, Rollino C, Praga M, Biancone L, Pani A, Feriozzi S, Polci R, Barratt J, Del Vecchio L, Locatelli F, Pierucci A, Caliskan Y, Perkowska-Ptasinska A, Durlik M, Moggia E, Ballarin JC, Wetzels JFM, Goumenos D, Papasotiriou M, Galesic K, Toric L, Papagianni A, Stangou M, Benozzi L, Cusinato S, Berg U, Topaloglu R, Maggio M, Ots-Rosenberg M, D'Amico M, Geddes C, Balafa O, Quaglia M, Cravero R, Lino Cirami C, Fellstrom B, Floege J, Egido J, Mallamaci F, Zoccali C.

Nephrol Dial Transplant. 2018 Nov 9. doi: 10.1093/ndt/gfy302. [Epub ahead of print]

PMID:
30418652
17.

Duration of Treatment with Corticosteroids and Recovery of Kidney Function in Acute Interstitial Nephritis.

Fernandez-Juarez G, Perez JV, Caravaca-Fontán F, Quintana L, Shabaka A, Rodriguez E, Gadola L, de Lorenzo A, Cobo MA, Oliet A, Sierra M, Cobelo C, Iglesias E, Blasco M, Galeano C, Cordon A, Oliva J, Praga M; Spanish Group for the Study of Glomerular Diseases (GLOSEN).

Clin J Am Soc Nephrol. 2018 Dec 7;13(12):1851-1858. doi: 10.2215/CJN.01390118. Epub 2018 Nov 5.

PMID:
30397027
18.

Returning to haemodialysis after kidney allograft failure: a survival study with propensity score matching.

Varas J, Pérez-Sáez MJ, Ramos R, Merello JI, de Francisco ALM, Luño J, Praga M, Aljama P, Pascual J; Optimizing Results in Dialysis (ORD) group.

Nephrol Dial Transplant. 2019 Apr 1;34(4):667-672. doi: 10.1093/ndt/gfy215.

PMID:
30053152
19.

CD19+ B-Cells, a New Biomarker of Mortality in Hemodialysis Patients.

Molina M, Allende LM, Ramos LE, Gutiérrez E, Pleguezuelo DE, Hernández ER, Ríos F, Fernández C, Praga M, Morales E.

Front Immunol. 2018 Jun 15;9:1221. doi: 10.3389/fimmu.2018.01221. eCollection 2018.

20.

Kidney transplant from uncontrolled donation after circulatory death donors maintained by nECMO has long-term outcomes comparable to standard criteria donation after brain death.

Molina M, Guerrero-Ramos F, Fernández-Ruiz M, González E, Cabrera J, Morales E, Gutierrez E, Hernández E, Polanco N, Hernández A, Praga M, Rodriguez-Antolín A, Pamplona M, de la Rosa F, Cavero T, Chico M, Villar A, Justo I, Andrés A.

Am J Transplant. 2019 Feb;19(2):434-447. doi: 10.1111/ajt.14991. Epub 2018 Aug 16.

PMID:
29947163
21.

Cancer immunotherapy: Great expectations in the world of oncology but a cause for kidney concern.

Redondo B, Moliz C, Alonso M, Paz-Ares L, Praga M, Morales E.

Nefrologia. 2019 Jan - Feb;39(1):94-96. doi: 10.1016/j.nefro.2018.05.002. Epub 2018 Jun 23. English, Spanish. No abstract available.

22.

Thrombocytopenia in the ICU: disseminated intravascular coagulation and thrombotic microangiopathies-what intensivists need to know.

Vincent JL, Castro P, Hunt BJ, Jörres A, Praga M, Rojas-Suarez J, Watanabe E.

Crit Care. 2018 Jun 13;22(1):158. doi: 10.1186/s13054-018-2073-2. No abstract available.

23.

Eculizumab as a treatment for atypical hemolytic syndrome secondary to carfilzomib.

Moliz C, Gutiérrez E, Cavero T, Redondo B, Praga M.

Nefrologia. 2019 Jan - Feb;39(1):86-88. doi: 10.1016/j.nefro.2018.02.005. Epub 2018 Apr 30. English, Spanish. No abstract available.

24.

IgA nephropathy: What patients are at risk of progression to end-stage renal disease and how should they be treated?

Praga M, Caravaca F, Yuste C, Cavero T, Hernández E, Morales E, Mérida E, Moreno JA, Sevillano A, Gutiérrez E.

Nefrologia. 2018 Jul - Aug;38(4):347-352. doi: 10.1016/j.nefro.2018.01.001. Epub 2018 Apr 7. English, Spanish. No abstract available.

25.

[Cardiovascular disease in lupus nephritis: An underestimated risk].

Caravaca-Fontán F, Praga M.

Hipertens Riesgo Vasc. 2018 Apr - Jun;35(2):51-53. doi: 10.1016/j.hipert.2018.02.003. Epub 2018 Mar 8. Spanish. No abstract available.

PMID:
29526670
26.

Heyde syndrome: Correction of anemia after aortic valve replacement in a hemodialysis patient.

Milla M, Hernández E, Mérida E, Yuste C, Rodríguez P, Praga M.

Nefrologia. 2018 May - Jun;38(3):327-329. doi: 10.1016/j.nefro.2017.05.002. Epub 2018 Mar 6. English, Spanish. No abstract available.

27.

Determinants of renal and patient outcomes in a Spanish cohort of patients with ANCA-associated vasculitis and renal involvement.

Marco H, Draibe J, Villacorta J, Quintana LF, Martin N, Garcia-Osuna R, Cabre C, Martín-Gómez MA, Balius A, Saurina A, Picazo M, Gich-Saladich I, Navarro-Díaz M, Praga M, Cavero T, Ballarin J, Díaz-Encarnación MM; Spanish Group for the Study of Glomerular Disease (GLOSEN).

Clin Rheumatol. 2018 Apr;37(4):1065-1074. doi: 10.1007/s10067-017-3973-2. Epub 2018 Mar 9.

PMID:
29520673
28.

Impact of anti-HCV direct antiviral agents on graft function and immunosuppressive drug levels in kidney transplant recipients: a call to attention in the mid-term follow-up in a single-center cohort study.

Fernández-Ruiz M, Polanco N, García-Santiago A, Muñoz R, Hernández AM, González E, Mercado VR, Fernández I, Aguado JM, Praga M, Andrés A.

Transpl Int. 2018 Aug;31(8):887-899. doi: 10.1111/tri.13118. Epub 2018 Feb 5.

29.

Paricalcitol Versus Calcifediol for Treating Hyperparathyroidism in Kidney Transplant Recipients.

Cruzado JM, Lauzurica R, Pascual J, Marcen R, Moreso F, Gutierrez-Dalmau A, Andrés A, Hernández D, Torres A, Beneyto MI, Melilli E, Manonelles A, Arias M, Praga M.

Kidney Int Rep. 2017 Sep 28;3(1):122-132. doi: 10.1016/j.ekir.2017.08.016. eCollection 2018 Jan.

30.

Hyperkalemia of non-renal origin in a hemodialysis patient.

Rodríguez P, Mérida E, Hernández E, Milla M, Praga M.

Nefrologia. 2018 Jan - Feb;38(1):96-97. doi: 10.1016/j.nefro.2017.01.005. English, Spanish. No abstract available.

31.

Lupus Nephritis in Males: Clinical Features, Course, and Prognostic Factors for End-Stage Renal Disease.

Urrestarazú A, Otatti G, Silvariño R, Garau M, Coitiño R, Alvarez A, Gonzalez E, Gadola L, Praga M, Noboa O.

Kidney Int Rep. 2017 Jun 16;2(5):905-912. doi: 10.1016/j.ekir.2017.05.011. eCollection 2017 Sep.

32.

A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis.

Vincenti F, Fervenza FC, Campbell KN, Diaz M, Gesualdo L, Nelson P, Praga M, Radhakrishnan J, Sellin L, Singh A, Thornley-Brown D, Veronese FV, Accomando B, Engstrand S, Ledbetter S, Lin J, Neylan J, Tumlin J; Focal Segmental Glomerulosclerosis Study Group.

Kidney Int Rep. 2017 Apr 7;2(5):800-810. doi: 10.1016/j.ekir.2017.03.011. eCollection 2017 Sep.

33.

Nephropathology and nephrology. The need for a change.

Vazquez Martul E, Praga M.

Nefrologia. 2018 May - Jun;38(3):247-249. doi: 10.1016/j.nefro.2017.11.002. Epub 2017 Dec 8. English, Spanish. No abstract available.

34.

Podocytes are new cellular targets of haemoglobin-mediated renal damage.

Rubio-Navarro A, Sanchez-Niño MD, Guerrero-Hue M, García-Caballero C, Gutiérrez E, Yuste C, Sevillano Á, Praga M, Egea J, Román E, Cannata P, Ortega R, Cortegano I, de Andrés B, Gaspar ML, Cadenas S, Ortiz A, Egido J, Moreno JA.

J Pathol. 2018 Mar;244(3):296-310. doi: 10.1002/path.5011. Epub 2018 Jan 10.

PMID:
29205354
35.

The Combination of Beta Blockers and Renin-Angiotensin System Blockers Improves Survival in Incident Hemodialysis Patients: A Propensity-Matched Study.

Luño J, Varas J, Ramos R, Merello I, Aljama P, MartinMalo A, Pascual J, Praga M; ORD Group.

Kidney Int Rep. 2017 Mar 7;2(4):665-675. doi: 10.1016/j.ekir.2017.03.001. eCollection 2017 Jul.

36.

Secondary thrombotic microangiopathy and eculizumab: A reasonable therapeutic option.

Román E, Mendizábal S, Jarque I, de la Rubia J, Sempere A, Morales E, Praga M, Ávila A, Górriz JL.

Nefrologia. 2017 Sep - Oct;37(5):478-491. doi: 10.1016/j.nefro.2017.01.006. Review. English, Spanish.

37.

Monoclonal gammopathies of renal significance.

Caravaca-Fontán F, Gutiérrez E, Delgado Lillo R, Praga M.

Nefrologia. 2017 Sep - Oct;37(5):465-477. doi: 10.1016/j.nefro.2017.03.012. Review. English, Spanish.

38.

A retrospective study of pregnancy-associated atypical hemolytic uremic syndrome.

Huerta A, Arjona E, Portoles J, Lopez-Sanchez P, Rabasco C, Espinosa M, Cavero T, Blasco M, Cao M, Manrique J, Cabello-Chavez V, Suñer M, Heras M, Fulladosa X, Belmar L, Sempere A, Peralta C, Castillo L, Arnau A, Praga M, Rodriguez de Cordoba S.

Kidney Int. 2018 Feb;93(2):450-459. doi: 10.1016/j.kint.2017.06.022. Epub 2017 Sep 12.

PMID:
28911789
39.

Gastrointestinal complications induced by sevelamer crystals.

Yuste C, Mérida E, Hernández E, García-Santiago A, Rodríguez Y, Muñoz T, Gómez GJ, Sevillano Á, Praga M.

Clin Kidney J. 2017 Aug;10(4):539-544. doi: 10.1093/ckj/sfx013. Epub 2017 Apr 10.

40.

Adverse effects of the renal accumulation of haem proteins. Novel therapeutic approaches.

Guerrero-Hue M, Rubio-Navarro A, Sevillano Á, Yuste C, Gutiérrez E, Palomino-Antolín A, Román E, Praga M, Egido J, Moreno JA.

Nefrologia. 2018 Jan - Feb;38(1):13-26. doi: 10.1016/j.nefro.2017.05.009. Epub 2017 Jun 28. Review. English, Spanish.

41.

Cortical necrosis: An uncommon cause of acute renal failure with a very poor outcome.

Rodríguez PM, Morales E, Sánchez Á, Milla M, Martínez MA, Praga M.

Nefrologia. 2017 May - Jun;37(3):339-341. doi: 10.1016/j.nefro.2016.10.017. English, Spanish. No abstract available.

42.

Elevated factor H-related protein 1 and factor H pathogenic variants decrease complement regulation in IgA nephropathy.

Tortajada A, Gutiérrez E, Goicoechea de Jorge E, Anter J, Segarra A, Espinosa M, Blasco M, Roman E, Marco H, Quintana LF, Gutiérrez J, Pinto S, Lopez-Trascasa M, Praga M, Rodriguez de Córdoba S.

Kidney Int. 2017 Oct;92(4):953-963. doi: 10.1016/j.kint.2017.03.041. Epub 2017 Jun 19.

PMID:
28637589
43.

Remission of Hematuria Improves Renal Survival in IgA Nephropathy.

Sevillano AM, Gutiérrez E, Yuste C, Cavero T, Mérida E, Rodríguez P, García A, Morales E, Fernández C, Martínez MA, Moreno JA, Praga M.

J Am Soc Nephrol. 2017 Oct;28(10):3089-3099. doi: 10.1681/ASN.2017010108. Epub 2017 Jun 7.

44.

Rituximab for Steroid-Dependent or Frequently Relapsing Idiopathic Nephrotic Syndrome in Adults: A Retrospective, Multicenter Study in Spain.

DaSilva I, Huerta A, Quintana L, Redondo B, Iglesias E, Draibe J, Praga M, Ballarín J, Díaz-Encarnación M; Spanish Group for the Study of Glomerular Diseases (GLOSEN).

BioDrugs. 2017 Jun;31(3):239-249. doi: 10.1007/s40259-017-0221-x.

PMID:
28534103
45.

Changes in the clinical presentation of immunoglobulin A nephropathy: data from the Spanish Registry of Glomerulonephritis.

Gutiérrez E, Praga M, Rivera F, Sevillano A, Yuste C, Goicoechea M, López-Gómez JM; all members of the Spanish Registry of Glomerulonephritis.

Nephrol Dial Transplant. 2018 Mar 1;33(3):472-477. doi: 10.1093/ndt/gfx058.

PMID:
28460086
46.

Calciphylaxis: Beyond CKD-MBD.

Fernández M, Morales E, Gutierrez E, Polanco N, Hernández E, Mérida E, Praga M.

Nefrologia. 2017 Sep - Oct;37(5):501-507. doi: 10.1016/j.nefro.2017.02.006. Epub 2017 Apr 5. English, Spanish.

47.

Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial.

Fellström BC, Barratt J, Cook H, Coppo R, Feehally J, de Fijter JW, Floege J, Hetzel G, Jardine AG, Locatelli F, Maes BD, Mercer A, Ortiz F, Praga M, Sørensen SS, Tesar V, Del Vecchio L; NEFIGAN Trial Investigators.

Lancet. 2017 May 27;389(10084):2117-2127. doi: 10.1016/S0140-6736(17)30550-0. Epub 2017 Mar 28.

PMID:
28363480
48.

Eculizumab in secondary atypical haemolytic uraemic syndrome.

Cavero T, Rabasco C, López A, Román E, Ávila A, Sevillano Á, Huerta A, Rojas-Rivera J, Fuentes C, Blasco M, Jarque A, García A, Mendizabal S, Gavela E, Macía M, Quintana LF, María Romera A, Borrego J, Arjona E, Espinosa M, Portolés J, Gracia-Iguacel C, González-Parra E, Aljama P, Morales E, Cao M, Rodríguez de Córdoba S, Praga M.

Nephrol Dial Transplant. 2017 Mar 1;32(3):466-474. doi: 10.1093/ndt/gfw453.

49.

Renal vasculitis presenting with acute kidney injury.

Villacorta J, Diaz-Crespo F, Acevedo M, Cavero T, Guerrero C, Praga M, Fernandez-Juarez G.

Rheumatol Int. 2017 Jun;37(6):1035-1041. doi: 10.1007/s00296-017-3697-2. Epub 2017 Mar 13.

PMID:
28289874
50.

Atypical hemolytic uremic syndrome (aHUS): essential aspects of an accurate diagnosis.

Laurence J, Haller H, Mannucci PM, Nangaku M, Praga M, Rodriguez de Cordoba S.

Clin Adv Hematol Oncol. 2016 Nov;14 Suppl 11(11):2-15. Review.

PMID:
27930620

Supplemental Content

Support Center